BNB PLUS CORP.
Business
BNB PLUS CORP. is a digital asset treasury company that has adopted BNB as its primary reserve asset while also commercializing nucleic acid production solutions through its LineaRx subsidiary. It offers BNB-focused treasury management and yield-generation activities (staking, liquid staking, liquidity provision, collateralization) and therapeutic DNA production solutions including LineaDNA, LineaRNAP and the integrated LineaIVT platform. The company operates through two principal businesses: a BNB digital asset treasury (DAT) strategy and a Therapeutic DNA Production Services segment (LineaRx). It distributes products and services directly to customers and via licensing or fee-for-service manufacturing to biopharmaceutical, diagnostics and DeFi counterparties across U.S. and international channels.
Summary from filing dated 2025-12-22
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2023 2023-09-30 | FY 2022 2022-09-30 | FY 2021 2021-09-30 |
|---|---|---|---|---|---|---|
| Total revenues | 2 | 2 | 13 | 18 | 9 | |
| Cost of product revenues | 1 | 1 | 8 | 13 | 5 | |
| Gross profit | 838,907 | 974,840 | 6 | 5 | 4 | |
| Selling, general and administrative | 11 | 11 | 13 | 15 | 13 | |
| Research and development | 6 | 4 | 4 | 4 | 4 | |
| Total operating expenses | 17 | 15 | 16 | 19 | 18 | |
| LOSS FROM OPERATIONS | −16 | −14 | −11 | −14 | −13 | |
| Interest income | 192,915 | 120,482 | 75,332 | — | — | |
| Transaction costs allocated to warrant liabilities | — | −633,198 | — | −2 | — | |
| Unrealized gain on change in fair value of warrants classified as a liability | 319,630 | 9 | 854,400 | 18 | 0 | |
| Unrealized loss on change in fair value of warrants classified as a liability-warrant modification | — | −394,000 | — | — | — | |
| Loss on issuance of warrants | — | −2 | — | −11 | 0 | |
| Other expense, net | −106,580 | −8,877 | 642 | −47,305 | −8,756 | |
| Loss before provision for income taxes | −16 | −7 | −10 | −8 | −14 | |
| Income tax provision benefit | 684,115 | 0 | 0 | 0 | 0 | |
| Net loss from continuing operations | −15 | −7 | — | — | — | |
| Net loss from discontinued operations, net of tax | −392,731 | −300,499 | — | — | — | |
| NET LOSS | −15 | −7 | −10 | −8 | −14 | |
| Less: Net loss attributable to noncontrolling interest | 188,522 | 95,785 | 75,857 | 2,168 | −8,003 | |
| NET LOSS attributable to BNB Plus Corp. | −15 | −7 | −10 | −8 | −14 | |
| Deemed dividend related to warrant modifications | −54 | −233,087 | — | 110,105 | — | |
| NET LOSS attributable to common stockholders | −69 | −7 | −10 | −8 | −14 | |
| Net loss per share attributable to common stockholders-continuing operations - basic (in dollars per share) | −133.47 | −1,310 | — | — | — | |
| Net loss per share attributable to common stockholders-continuing operations - diluted (in dollars per share) | −133.47 | −1,310 | — | — | — | |
| Net loss per share attributable to common stockholders-discontinued operations - basic (in dollars per share) | −0.76 | −56.83 | — | — | — | |
| Net loss per share attributable to common stockholders-discontinued operations - diluted (in dollars per share) | −0.76 | −56.83 | — | — | — | |
| Net loss income per share attributable to common stockholders - basic (in dollars per share) | −134.23 | −1,366 | −15.21 | −0.93 | −2.07 | |
| Net loss income per share attributable to common stockholders - diluted (in dollars per share) | −134.23 | −1,366 | −15.21 | −0.93 | −2.07 | |
| Weighted average shares outstanding- basic (in shares) | 517,671 | 5,288 | 653,771 | 9 | 7 | |
| Weighted average shares outstanding- diluted (in shares) | 517,671 | 5,288 | 653,771 | 9 | 7 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-11-30 | FY 2024 2024-09-30 | FY 2023 2023-09-30 | FY 2022 2022-09-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 2 | 10 | 6 | 7 | 15 | |
| Accounts receivable, net of allowance for credit losses of $0 and $75,000 at September 30, 2025 and 2024, respectively | 237,400 | — | 328,252 | 255,502 | 3 | |
| Inventories | 84,102 | — | 432,725 | 330,027 | 602,244 | |
| Prepaid expenses and other current assets | 242,153 | — | 756,185 | 389,241 | 1 | |
| Current assets of discontinued operations | 6,971 | — | 678,146 | — | — | |
| Total current assets | 2 | — | 8 | 8 | 20 | |
| Property and equipment, net | 242,720 | — | 458,895 | 838,270 | 2 | |
| Noncurrent assets of discontinued operations | — | — | 94,337 | — | — | |
| Restricted cash | 750,000 | — | 750,000 | 750,000 | — | |
| Security deposit | 2,977 | — | — | — | — | |
| Intangible assets | — | — | 3 | 3 | — | |
| Operating right of use asset | 193,249 | — | 739,162 | 1 | — | |
| Deferred offering costs | 1 | — | — | — | — | |
| Total assets | 4 | — | 13 | 14 | 22 | |
| Accounts payable and accrued liabilities | 2 | — | 2 | 2 | 4 | |
| Operating lease liability, current | 193,250 | — | 545,912 | 498,598 | — | |
| Deferred revenue | 12,285 | — | 58,785 | 76,435 | 563,557 | |
| Current liabilities of discontinued operations | — | — | 56,061 | — | — | |
| Total current liabilities | 2 | — | 2 | 3 | 4 | |
| Long term accrued liabilities | 31,467 | — | 31,467 | 31,467 | 31,467 | |
| Deferred revenue, long term | — | — | 194,000 | 194,000 | — | |
| Operating lease liability, long term | — | — | 193,249 | 739,162 | — | |
| Deferred tax liability, net | — | — | 684,115 | 684,115 | — | |
| Warrants classified as a liability | 370 | — | 320,000 | 4 | 5 | |
| Total liabilities | 2 | — | 4 | 9 | 9 | |
| Commitments and contingencies (Note G) | — | — | — | — | — | |
| Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of September 30, 2025 and 2024 | — | — | — | — | 0 | |
| Common stock, par value $0.001 per share; 200,000,000 shares authorized as of September 30, 2025 and 2024; 1,662,601 and 13,755 shares issued and outstanding as of September 30, 2025 and 2024, respectively | 1,663 | — | 14 | 683 | 12,909 | |
| Additional paid in capital | 381 | — | 319 | 307 | 305 | |
| Accumulated deficit | −379 | — | −310 | −302 | −293 | |
| BNB Plus Corp., Inc. stockholders' equity | 2 | — | 9 | 5 | 13 | |
| Noncontrolling interest | −363,054 | — | −174,532 | −78,747 | −2,890 | |
| Total equity | 2 | — | 9 | 5 | 13 | |
| Total liabilities and equity | 4 | — | 13 | 14 | 22 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2023 2023-09-30 | FY 2022 2022-09-30 | FY 2021 2021-09-30 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 384,165 | 432,595 | 1 | 1 | 844,438 | |
| Deferred income tax benefit | −684,115 | — | — | — | — | |
| Impairment of intangible asset | 3 | — | — | — | — | |
| Loss on write-off of property and equipment | 145,131 | — | 62,000 | — | — | |
| Unrealized gain on change in fair value of warrants classified as a liability | −319,630 | −9 | −854,400 | — | — | |
| Transaction costs allocated to warrant liabilities | — | 633,198 | — | — | — | |
| Shares issued Spindle earnout | — | 17,112 | — | — | — | |
| Stock-based compensation | 102,021 | 572,293 | 1 | 3 | 2 | |
| Bad debt expense | 6,465 | — | −239,043 | 269,451 | 28,629 | |
| Accounts receivable | −5,613 | −115,286 | 3 | −532,957 | −3 | |
| Inventories | 348,623 | −118,591 | 272,217 | 767,689 | −872,566 | |
| Prepaid expenses, other current assets and deposits | 511,055 | −391,687 | 767,812 | −493,220 | 30,415 | |
| Accounts payable and accrued liabilities | −516,716 | −412,172 | −1 | 930,497 | 94,711 | |
| Deferred revenue | 43,500 | −17,650 | −293,122 | 282,557 | −230,036 | |
| Net cash used in operating activities from continuing operations | −12 | −14 | — | — | — | |
| Purchase of property and equipment | −313,121 | −407,904 | −78,448 | −489,553 | −3 | |
| Net cash used in investing activities from continuing operations | −313,121 | −407,904 | — | — | — | |
| Net proceeds from exercise of warrants | 3 | 394 | — | 4 | 3 | |
| Capitalized offering costs | −166,341 | — | — | — | — | |
| Net proceeds from issuance of common stock and pre-funded warrants | 6 | 13 | — | — | — | |
| Net cash provided by financing activities from continuing operations | 8 | 13 | — | 18 | 15 | |
| Cash used in operating activities | −276,041 | −121,182 | — | — | — | |
| Cash provided by investing activities | 21,000 | 0 | — | — | — | |
| Net cash used in discontinued operations | −255,041 | −121,182 | — | — | — | |
| Net decrease in cash, cash equivalents and restricted cash | −5 | −720,705 | −7 | 9 | −1 | |
| Cash paid during period for income taxes | 2 | 7 | — | 0 | 0 | |
| Transaction costs included in accounts payable | 843,728 | — | — | — | — | |
| Deemed dividend warrant modifications | 54 | 233,087 | — | 110,105 | 0 | |
| Warrants issued, cashlessly | 1,314 | — | — | 26 | 0 | |
| Property and equipment acquired and included in accounts payable | — | 3,484 | — | 0 | 181,807 |